HOUSTON, March 10, 2020 /PRNewswire/ -- Moleculin Biotech,
Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical
stage pharmaceutical company with a broad portfolio of drug
candidates targeting highly resistant tumors, announced that Dr.
Hongbo Zhai, former Senior Faculty
and Supervisor of Postdoctoral Fellows at University of California San Francisco, has joined
Moleculin's Science Advisory Board.
"We are honored to have Dr. Zhai, who brings two decades of
research and development experience in pharmaceuticals and
biotechnology, join our Science Advisory Board," commented
Walter Klemp, Moleculin's Chairman
and CEO. "Dr. Zhai will be focused on identifying opportunities in
oncology, dermatology, and virology within China for our three drug technologies. We look
forward to building our business in China through Dr. Zhai's extensive network and
relationships."
As a former board-certified dermatologist in China, Dr. Hongbo
Zhai has extensive experience with Chinese regulatory
authorities including the CFDA and the Ministry of Public Health.
Dr. Zhai has contributed to the development of products in
collaboration with global Fortune 500 companies such as Procter
& Gamble, Pfizer, Johnson & Johnson, 3M Pharmaceuticals, and L'OREAL and has published
more than 120 scientific articles in his research areas.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical
company focused on the development of a broad portfolio of oncology
drug candidates for the treatment of highly resistant tumors. The
Company's clinical stage drugs are: Annamycin, a Next Generation
Anthracycline, designed to avoid multidrug resistance mechanisms
with little to no cardiotoxicity being studied for the treatment of
relapsed or refractory acute myeloid leukemia, more commonly
referred to as AML, WP1066, an Immune/Transcription Modulator
capable of inhibiting p-STAT3 and other oncogenic transcription
factors while also stimulating a natural immune response, targeting
brain tumors, pancreatic cancer and hematologic malignancies, and
WP1220, an analog to WP1066, for the topical treatment of cutaneous
T-cell lymphoma. Moleculin is also engaged in preclinical
development of additional drug candidates, including additional
Immune/Transcription Modulators, as well as compounds capable of
Metabolism/Glycosylation Inhibition.
For more information about the Company, please
visit http://www.moleculin.com.
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability for Moleculin to
build its business activities in China. Although Moleculin believes that the
expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. Moleculin Biotech has attempted to
identify forward-looking statements by terminology including
''believes,'' ''estimates,'' ''anticipates,'' ''expects,''
''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,''
''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. These statements are
only predictions and involve known and unknown risks,
uncertainties, and other factors, including those discussed under
Item 1A. "Risk Factors" in our most recently filed Form 10-K filed
with the Securities and Exchange Commission ("SEC") and updated
from time to time in our Form 10-Q filings and in our other public
filings with the SEC. Any forward-looking statements contained in
this release speak only as of its date. We undertake no obligation
to update any forward-looking statements contained in this release
to reflect events or circumstances occurring after its date or to
reflect the occurrence of unanticipated events.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/moleculin-announces-dr-hongbo-zhai-joins-science-advisory-board-301020345.html
SOURCE Moleculin Biotech, Inc.